Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
McKesson
Colorcon
Mallinckrodt
Moodys

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Epratuzumab

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Epratuzumab: Patents, clinical trial progress, indications

Epratuzumab is an investigational drug.

There have been 26 clinical trials for Epratuzumab. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2010.

The most common disease conditions in clinical trials are Lupus Erythematosus, Systemic, Lymphoma, and Leukemia, Lymphoid. The leading clinical trial sponsors are UCB Pharma, Immunomedics, Inc., and Nantes University Hospital.

Recent Clinical Trials for Epratuzumab
TitleSponsorPhase
Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALLNantes University HospitalPhase 2
Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic LeukemiaImmunomedics, Inc.Phase 1/Phase 2
Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic LeukemiaInstitut Cancerologie de l'OuestPhase 1/Phase 2

See all Epratuzumab clinical trials

Clinical Trial Summary for Epratuzumab

Top disease conditions for Epratuzumab
Top clinical trial sponsors for Epratuzumab

See all Epratuzumab clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Express Scripts
Colorcon
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.